



# Interpace Pharma Solutions™

Empowering Better Medicine

## Special Statement Regarding COVID-19

Dear Valued Customer

Interpace Pharma Solutions is committed to ensuring the continuance of all business practice with the limit of public health concerns with COVID-19. We understand that today's environment is unprecedented and challenging for many. I want to assure you of our full support and also update you on our evolving approach to COVID-19 in light of current global volatility.

We are taking appropriate steps to ensure the resiliency of our business operations, while safeguarding the health and well-being of employees, clients and suppliers.

We are currently operating "business as usual", and have initiated our Business Continuity Plan (BCP). We are vigorously monitoring the local, national, and international agencies related to receiving clinical specimens into our laboratory facilities, and are incorporating the guidance from the experts at the US Centers for Disease Control and Prevention (CDC) into our daily activities to ensure the health of our employees. We have informed our Interpace family of risk mitigation from the CDC recommendations.

Finally, we are actively in contact with our respective logistics partners related to all shipment notifications to ensure we receive clinical specimens at our facilities without delay.

If a change in the Interpace BCP plan occurs due to the evolving circumstances in our communities or regions, you will be promptly informed by our response team.

We appreciate your understanding that, as a customer, your experience may look different as we navigate through this time together. If you know of any disruptions in any of the projects that Interpace Pharma Solutions is managing, please let us know. We will continue to stay close to our partners and local health officials, and we are optimistic this will be a temporary situation.

Warm Regards,

**Jay Roberts**

President

Interpace Pharma Solutions

